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Conclusion
 Complete Leachables Blank Run demonstrates that the 
downstream purification unit operations provide a level of 
removal of leachables throughout the process
 Study confirms and supports direction of industry to focus 
on evaluating E&L from the bioreactor and from BDS 
storage through to drug product
 Study brings confidence in patient safety in regard to 
leachables from single-use processes as demonstrated by 
evaluating patient safety thresholds
 Final filling operations utilize primarily the same MoC’s as 
evaluated here, providing confidence that leachables 
should not pose a safety hazard
 Provides confidence that leachates from the Provantage® 
ClinicReady template will not adversely impact the clinical 
studies vs. a traditional process and that the 
materials/media contained within the Provantage® 
ClinicReady template are commercially viable from a 
material safety standpoint
Study Methodology
A simulated Mab process was executed using the process template 
shown above.  Samples were collected from each process 
intermediate pool as indicated by the blue circles. Process fluids 
were comprised of the standard cell culture media, feeds, and  
buffers without the presence of cells or product protein.  The 
process utilized single-use materials during all primary unit 
operations and ancillary operations such as media and buffer prep.  
All process  and ancillary filters were pre-flushed  per user guide 
instructions.  The process was operated on a 5 day/10 hr. shift 
basis during the downstream process (DSP).  Most  buffers and 
product intermediate pools were stored overnight and in some 
cases over the weekend; no attempt to was made to minimize hold 
times by running 24-hour operations.
Abstract
The implementation of single-use technologies for 
pharmaceutical product development continues to gain 
momentum; this trend is due to the advantages of increased 
flexibility, speed of implementation and lower capital 
investment. In particular, they are seen as a means to 
accelerate the production of material for clinical trials. 
However, a primary concern regarding the use of such 
technologies is the level and impact of leachables in the final 
drug substance. Typically this concern is addressed through 
a risk assessment utilizing extractable substances data 
based on model solvent extractions from individual 
components and devices. 
However, little if any data has been published where 
leachables are evaluated under actual process conditions 
through a complete single-use clinical-scale process train.  
We have addressed this by completing a pilot scale 100 L 
“mock” mAb production and purification where the cells, and 
hence mAb protein, are absent but where the bioreactor was 
run for the normal duration with cell culture media and feeds, 
and the DSP train utilized all the standard process devices, 
buffers, conditions, and procedures. Data will be presented 
on the leachables profile throughout the entire production 
process and, where relevant placed within the context of a 
patient  risk assessment.
E&L PDA Definitions
Extractables
“Any chemical component that is removed from a 
material by the application of an artificial or exaggerated 
force (e.g., solvent, temperature or time).”
Determined under “worst-case” conditions following 
the Model Stream approach.
Leachables
“A chemical component that migrates from a contact 
surface into a drug product or process fluid during 
storage or normal use conditions.”
Determined with the product under normal 
processing/storage conditions.
Total Mass of Leachables through Process
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E&L Evaluation Process
Compliance with the regulations is achieved not by the 
execution of a single discrete study or report, but rather by the 
conduct of a step-wise and risk based process as outlined 
below. The main steps of an evaluation are listed here.  These 
steps are a condensation of the process flow diagrams / 
decisions trees that are advocated by groups like BPSA 
(Bioprocess Systems Alliance) and PQRI (Packaging Quality 
Research Institute). 
• Build in quality by selecting well qualified and safe materials 
assess overall risk of materials on product / patient
• Generate extractables information in model solvents under 
worst-case conditions
• Patient safety risk assessment
• Conduct leachables studies as necessary 
• Demonstrate non-toxicity
A Fully Single-use Mab Process
Unit 
Operation








Bioreactor n/a 1 1 1 2
Harvest 2.64 m2 2 2 1 2
Capture Chrom 1.6 L 5 3 5 8
CEX Chrom 1.6 L 2 2 1 6
AEX Chrom 50 mL 2 2 3
4
Virus Filtration 0.14 m2 2 2 1 3
TFF-UFDF 0.5 m2 1 2 1 4
BDS Filtration 0.029 m2 0 1 1 0
Summary of Material Exposure
In the table presented we can gain an appreciation for the vast 
amount and number of product contact materials that are included 
in the Mab template and this process run.  A number of sterile 
filters, single-use bags, and flowpaths (tubing and connectors) are 
associated with each unit operation comprising more than 150 
components. 




Mobius® 200 L 
Bioreactor
Millistak+® D0HC + 
X0HC  Pod filters 
ProSep® Ultra Plus 
resin




















































Patient Exposure to Leachables in BDS










Exposure (PDE) Limit 
µg/day
0.11 105.0 11.6 3750
Based on mAb high dosing regimen of 1050 mg API/1 week
A Look at Individual compounds
Need for Patient Safety Evaluation
 The concentration of total leachables would fall above a 
worst-case threshold exposure limit of 1.5 ug/day based on 
the >10 year TTC-based acceptable intake of a mutagenic 
impurity
 Toxicity of individual compounds need to be further 
evaluated to demonstrate the concentrations are below 
safety thresholds
 The leached compound identified in the greatest 
concentration within the BDS after 7 days storage was 
Hexanal (CAS 66-25-1)
 Hexanal is a VOC identified and quantified via HS GCMS at 
a concentration of 110 ppb or  0.11 ppm
 Ex. A PDE for  Butanal/Pentanal was established at 3.75 
mg/person/day
200L SU Bioreactor





 13 days at process temperature & agitation
 Sampled at t=0, t=13 days
 Day 13 harvest followed by full DSP
 Full-scale operations with all devices/resins
 All unit operations utilized single-use systems & flowpaths
 All process buffers prepped & stored in SU bags
 Sampling from each buffer bag/process intermediate pool
 GC-MS (VOC and sVOC)









<0.1 ppm in total VOC leachables. 
The compounds include: alkanes, 
aldehydes, ketones.
 0.38 ppm in total SVOC 
leachables. The compounds 
include:  branched alkenes, long 
chain alcohols, siloxanes and 2,4-
di-tert-butylphenol.
 ICP and LCMS did not observe 
any compounds. 
Day 7
 0.21 ppm in total VOC leachables. 
The compounds include: alkanes, 
aldehydes, ketones.
 0.67 ppm in total SVOC 
leachables. The compounds 
include: branched alkenes, long 
chain alcohols, siloxanes and 2,4-
di-tert-butylphenol.
 ICP and LCMS did not observe 
any compounds. 
Summary of Bioreactor Samples
Day 0
<0.1 ppm in total VOC 
leachables. These compounds 
include: alkanes, aldehydes, 
ketones.
 0.95 ppm in total SVOC 
leachables. These compounds 
include: branched alkenes, long 
chain alcohols, ketones, and 
siloxanes.  
 ICP and LCMS did not observe 
any compounds except those 
which are part of the media 
formulation.
Day 13
 0.22 ppm in total VOC leachables. 
These compounds include: 
alkanes, aldehydes, ketones.
 1.34 ppm in total SVOC 
leachables. These compounds 
include: branched alkenes, long 
chain alcohols, aldehydes, and 
siloxanes. 
 ICP did not observe any 
compounds except those which are 
part of the media formulation.
Trace amount (<20 ppb) of bis-di-
tert-butyl phenol phosphate (bis-
DtBPP).
Summary of Bulk Drug Substance Samples
 Results did not indicate an accumulation of Leachables 
through the process






























Note: 81L out of 150L of  the day 13 
Bioreactor fluid was carried into the DSP 
